FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136309976> ?p ?o ?g. }

• W3136309976 endingPage "e002096" @default.
• W3136309976 startingPage "e002096" @default.
• W3136309976 abstract "Oncolytic viruses reduce tumor burden in animal models and have generated promising results in clinical trials. However, it is likely that oncolytic viruses will be more effective when used in combination with other therapies. Current therapeutic approaches, including chemotherapeutics, come with dose-limiting toxicities. Another option is to combine oncolytic viruses with immunotherapeutic approaches.Using experimental models of metastatic 4T1 breast cancer and ID8 ovarian peritoneal carcinomatosis, we examined natural killer T (NKT) cell-based immunotherapy in combination with recombinant oncolytic vesicular stomatitis virus (VSV) or reovirus. 4T1 mammary carcinoma cells or ID8 ovarian cancer cells were injected into syngeneic mice. Tumor-bearing mice were treated with VSV or reovirus followed by activation of NKT cells via the intravenous administration of autologous dendritic cells loaded with the glycolipid antigen α-galactosylceramide. The effects of VSV and reovirus on immunogenic cell death (ICD), cell viability and immunogenicity were tested in vitro.VSV or reovirus treatments followed by NKT cell activation mediated greater survival in the ID8 model than individual therapies. The regimen was less effective when the treatment order was reversed, delivering virus treatments after NKT cell activation. In the 4T1 model, VSV combined with NKT cell activation increased overall survival and decreased metastatic burden better than individual treatments. In contrast, reovirus was not effective on its own or in combination with NKT cell activation. In vitro, VSV killed a panel of tumor lines better than reovirus. VSV infection also elicited greater increases in mRNA transcripts for proinflammatory cytokines, chemokines, and antigen presentation machinery compared with reovirus. Oncolytic VSV also induced the key hallmarks of ICD (calreticulin mobilization, plus release of ATP and HMGB1), while reovirus only mobilized calreticulin.Taken together, these results demonstrate that oncolytic VSV and NKT cell immunotherapy can be effectively combined to decrease tumor burden in models of metastatic breast and ovarian cancers. Oncolytic VSV and reovirus induced differential responses in our models which may relate to differences in virus activity or tumor susceptibility." @default.
• W3136309976 created "2021-03-29" @default.
• W3136309976 creator A5006500798 @default.
• W3136309976 creator A5040696238 @default.
• W3136309976 creator A5041359696 @default.
• W3136309976 creator A5057567376 @default.
• W3136309976 creator A5064461704 @default.
• W3136309976 creator A5083239377 @default.
• W3136309976 creator A5088476911 @default.
• W3136309976 date "2021-03-01" @default.
• W3136309976 modified "2023-10-10" @default.
• W3136309976 title "Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis" @default.
• W3136309976 cites W1554694720 @default.
• W3136309976 cites W1609608388 @default.
• W3136309976 cites W1936207051 @default.
• W3136309976 cites W1971995358 @default.
• W3136309976 cites W1973393242 @default.
• W3136309976 cites W1976690411 @default.
• W3136309976 cites W1988787723 @default.
• W3136309976 cites W1991505853 @default.
• W3136309976 cites W2001978717 @default.
• W3136309976 cites W2006519197 @default.
• W3136309976 cites W2011513757 @default.
• W3136309976 cites W2015720380 @default.
• W3136309976 cites W2016612145 @default.
• W3136309976 cites W2017095275 @default.
• W3136309976 cites W2023310830 @default.
• W3136309976 cites W2024040080 @default.
• W3136309976 cites W2030132880 @default.
• W3136309976 cites W2036074330 @default.
• W3136309976 cites W2064116640 @default.
• W3136309976 cites W2076203883 @default.
• W3136309976 cites W2081796577 @default.
• W3136309976 cites W2089664117 @default.
• W3136309976 cites W2090599158 @default.
• W3136309976 cites W2093424661 @default.
• W3136309976 cites W2098405100 @default.
• W3136309976 cites W2115935733 @default.
• W3136309976 cites W2128616119 @default.
• W3136309976 cites W2134339596 @default.
• W3136309976 cites W2135054826 @default.
• W3136309976 cites W2150701651 @default.
• W3136309976 cites W2152041843 @default.
• W3136309976 cites W2153960708 @default.
• W3136309976 cites W2157046375 @default.
• W3136309976 cites W2161417315 @default.
• W3136309976 cites W2207230085 @default.
• W3136309976 cites W2265669938 @default.
• W3136309976 cites W2339252122 @default.
• W3136309976 cites W2416659570 @default.
• W3136309976 cites W2513362995 @default.
• W3136309976 cites W2536322725 @default.
• W3136309976 cites W2594948128 @default.
• W3136309976 cites W2744993513 @default.
• W3136309976 cites W2766991138 @default.
• W3136309976 cites W2807944903 @default.
• W3136309976 cites W2914345456 @default.
• W3136309976 cites W2982474032 @default.
• W3136309976 cites W4211214747 @default.
• W3136309976 doi "https://doi.org/10.1136/jitc-2020-002096" @default.
• W3136309976 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7970295" @default.
• W3136309976 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33722907" @default.
• W3136309976 hasPublicationYear "2021" @default.
• W3136309976 type Work @default.
• W3136309976 sameAs 3136309976 @default.
• W3136309976 citedByCount "28" @default.
• W3136309976 countsByYear W31363099762021 @default.
• W3136309976 countsByYear W31363099762022 @default.
• W3136309976 countsByYear W31363099762023 @default.
• W3136309976 crossrefType "journal-article" @default.
• W3136309976 hasAuthorship W3136309976A5006500798 @default.
• W3136309976 hasAuthorship W3136309976A5040696238 @default.
• W3136309976 hasAuthorship W3136309976A5041359696 @default.
• W3136309976 hasAuthorship W3136309976A5057567376 @default.
• W3136309976 hasAuthorship W3136309976A5064461704 @default.
• W3136309976 hasAuthorship W3136309976A5083239377 @default.
• W3136309976 hasAuthorship W3136309976A5088476911 @default.
• W3136309976 hasBestOaLocation W31363099761 @default.
• W3136309976 hasConcept C121608353 @default.
• W3136309976 hasConcept C126322002 @default.
• W3136309976 hasConcept C139563560 @default.
• W3136309976 hasConcept C159047783 @default.
• W3136309976 hasConcept C203014093 @default.
• W3136309976 hasConcept C2522874641 @default.
• W3136309976 hasConcept C2776090121 @default.
• W3136309976 hasConcept C2777701055 @default.
• W3136309976 hasConcept C2779057330 @default.
• W3136309976 hasConcept C2780427987 @default.
• W3136309976 hasConcept C49744831 @default.
• W3136309976 hasConcept C502942594 @default.
• W3136309976 hasConcept C71924100 @default.
• W3136309976 hasConcept C82210918 @default.
• W3136309976 hasConcept C86803240 @default.
• W3136309976 hasConcept C8891405 @default.
• W3136309976 hasConceptScore W3136309976C121608353 @default.
• W3136309976 hasConceptScore W3136309976C126322002 @default.
• W3136309976 hasConceptScore W3136309976C139563560 @default.
• W3136309976 hasConceptScore W3136309976C159047783 @default.

• next